Axogen/$AXGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axogen
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Ticker
$AXGN
Sector
Primary listing
Employees
452
Headquarters
Website
Axogen Metrics
BasicAdvanced
$755M
-
-$0.10
0.99
-
Price and volume
Market cap
$755M
Beta
0.99
52-week high
$21.00
52-week low
$9.22
Average daily volume
1.5M
Financial strength
Current ratio
4.14
Quick ratio
2.32
Long term debt to equity
60.615
Total debt to equity
62.583
Interest coverage (TTM)
0.22%
Profitability
EBITDA (TTM)
8.649
Gross margin (TTM)
74.27%
Net profit margin (TTM)
-2.29%
Operating margin (TTM)
0.84%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
0.54%
Return on equity (TTM)
-4.48%
Valuation
Price to revenue (TTM)
3.659
Price to book
6.69
Price to tangible book (TTM)
7.07
Price to free cash flow (TTM)
214.65
Free cash flow yield (TTM)
0.47%
Free cash flow per share (TTM)
0.076
Growth
Revenue change (TTM)
17.17%
Earnings per share change (TTM)
-73.42%
3-year revenue growth (CAGR)
16.61%
10-year revenue growth (CAGR)
25.58%
3-year earnings per share growth (CAGR)
-48.62%
10-year earnings per share growth (CAGR)
-18.44%
What the Analysts think about Axogen
Analyst ratings (Buy, Hold, Sell) for Axogen stock.
Bulls say / Bears say
Axogen reported second quarter 2025 GAAP revenue of $56.7 million, an 18.3% year-over-year increase that exceeded analyst estimates, reflecting strong demand across all nerve repair segments (TradingView News)
Management raised full-year 2025 revenue guidance to at least $219 million, implying at least 17% growth, signaling confidence in sustained commercial momentum (SEC.gov)
The FDA accepted Axogen’s Biologics License Application for Avance® Nerve Graft with a PDUFA goal date of September 5, 2025, and the company completed key regulatory milestones including late-cycle and pre-licensing inspections, positioning for potential market exclusivity (SEC.gov)
Axogen expects one-time costs related to the anticipated Avance® Nerve Graft BLA approval to negatively impact gross margin by approximately 1%, which could weigh on profitability (SEC.gov)
Gross margin in the first half of 2025 contracted due to costs from new processing center setup, indicating potential pressure on margins until efficiencies improve (Investing.com)
Despite expansion, commercial payer coverage for Axogen’s nerve repair solutions is only around 55% of lives, leaving nearly half of the addressable market with reimbursement uncertainty (SEC.gov)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Axogen Financial Performance
Revenues and expenses
Axogen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axogen stock?
Axogen (AXGN) has a market cap of $755M as of September 16, 2025.
What is the P/E ratio for Axogen stock?
The price to earnings (P/E) ratio for Axogen (AXGN) stock is 0 as of September 16, 2025.
Does Axogen stock pay dividends?
No, Axogen (AXGN) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Axogen dividend payment date?
Axogen (AXGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Axogen?
Axogen (AXGN) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.